Literature DB >> 4413363

Experience with Depo-provera as an injectable contraceptive.

P C Schwallie.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4413363

Source DB:  PubMed          Journal:  J Reprod Med        ISSN: 0024-7758            Impact factor:   0.142


× No keyword cloud information.
  7 in total

Review 1.  Optimisation of treatment by applying programmable rate-controlled drug delivery technology.

Authors:  Yie W Chien; Senshang Lin
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Retinal venous occlusion associated with depot medroxyprogesterone acetate.

Authors:  Byron F Deen; R Keith Shuler; Sharon Fekrat
Journal:  Br J Ophthalmol       Date:  2007-09       Impact factor: 4.638

Review 3.  Long acting contraceptives. Present status.

Authors:  G Benagiano; F M Primiero
Journal:  Drugs       Date:  1983-06       Impact factor: 9.546

4.  The pharmacokinetics of high-dose medroxyprogesterone acetate (MPA) in the therapy of advanced breast cancer.

Authors:  H C Blossey; H H Bartsch; D Kanne; J Koebberling; G A Nagel
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 5.  Depot-medroxyprogesterone acetate (DMPA) and cancer: memorandum from a WHO meeting.

Authors: 
Journal:  Bull World Health Organ       Date:  1986       Impact factor: 9.408

Review 6.  Pharmacokinetics, metabolism and serum concentrations of progestins used in contraception.

Authors:  Alexis J Bick; Renate Louw-du Toit; Salndave B Skosana; Donita Africander; Janet P Hapgood
Journal:  Pharmacol Ther       Date:  2020-12-13       Impact factor: 13.400

7.  Effect of medroxyprogesterone acetate on the response of the rat mammary gland to carcinogenesis.

Authors:  I H Russo; P Gimotty; M Dupuis; J Russo
Journal:  Br J Cancer       Date:  1989-02       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.